According to the findings, certain gut microbial signatures might have indicated moderate cognitive impairment, and the MMKD may have the ability to alter the gut microbiome and metabolites in connection with improved CSF AD biomarkers, as assessed by measurements of the gut flora, fecal short-chain fatty acids (SCFAs), and AD indicators in CSF such as amyloid β (Aβ)-40 and Aß-42, total tau, and phosphorylated tau-181 (tau-p181) to quantify the cognitive changes. The gene discussed is MAPT; the disease is Alzheimer disease.